stoxline Quote Chart Rank Option Currency Glossary
Cytokinetics, Incorporated (CYTK)
59.53  -0.39 (-0.65%)    05-17 16:00
Open: 59.62
High: 60.47
Volume: 974,803
Pre. Close: 59.92
Low: 58.64
Market Cap: 6,242(M)
Technical analysis
2024-05-17 4:44:57 PM
Short term     
Mid term     
Targets 6-month :  76.62 1-year :  83.62
Resists First :  65.6 Second :  71.59
Pivot price 62.38
Supports First :  55.9 Second :  46.51
MAs MA(5) :  59.43 MA(20) :  63.22
MA(100) :  73.43 MA(250) :  49.79
MACD MACD :  -2.3 Signal :  -2
%K %D K(14,3) :  32.5 D(3) :  30.3
RSI RSI(14): 36.2
52-week High :  110.25 Low :  25.97
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CYTK ] has closed above bottom band by 20.5%. Bollinger Bands are 57.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 60.5 - 60.9 60.9 - 61.24
Low: 57.87 - 58.26 58.26 - 58.59
Close: 58.95 - 59.59 59.59 - 60.13
Company Description

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Headline News

Fri, 17 May 2024
Cytokinetics CEO Blum says positioned to market heart drug aficamten by itself - Seeking Alpha

Fri, 17 May 2024
Cytokinetics to Host Muscle Seminar -

Thu, 16 May 2024
Charles Schwab Investment Management Inc. Acquires 33,257 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat

Thu, 16 May 2024
Charles Schwab Investment Management Inc. Grows Position in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World

Wed, 15 May 2024
Thornburg Investment Management Inc. Lowers Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat

Wed, 15 May 2024
Could The Cytokinetics, Incorporated (NASDAQ:CYTK) Ownership Structure Tell Us Something Useful? - Yahoo Lifestyle UK

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 105 (M)
Held by Insiders 1.0125e+008 (%)
Held by Institutions 0.5 (%)
Shares Short 13,230 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -4.8495e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -15 %
Return on Assets (ttm) 117.9 %
Return on Equity (ttm) -36.7 %
Qtrly Rev. Growth 3.75e+006 %
Gross Profit (p.s.) -113.75
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -5.5 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio -1
Price to Book value 0
Price to Sales 0
Price to Cash Flow -11.02
Stock Dividends
Dividend 0
Forward Dividend 1.367e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android